Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000929638-25-003514
Filing Date
2025-09-18
Accepted
2025-09-18 17:47:12
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9122
2 exhibit99-1.htm EX-99.1 7447
  Complete submission text file 0000929638-25-003514.txt   18354
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Subject) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94600 | Film No.: 251324487
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 444 MADISON AVENUE 41ST FLOOR NEW YORK NY 10022
Business Address 444 MADISON AVENUE 41ST FLOOR NEW YORK NY 10022 646-701-7428
Lind Global Fund III LP (Filed by) CIK: 0002071860 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G